Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 347

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 347
---
 of the
Company’s board of directors, respectively.

NOTE 14 – SUBSEQUENT EVENTS During the period from April 1, 2025 to May 14, 2025, 23shares of Series B Preferred Stock were converted into 63,281shares of Common Stock. The conversion ratio was based on the Series B Certificate of Designations and reflected the applicable Alternate Conversion Price. During the period from April 1, 2025 to May 14, 2025, 520shares of Series C Preferred Stock were converted into 2,080,000shares of Common Stock. The conversion ratio was based on the Series C Certificate of Designations and reflected the applicable Alternate Conversion Price. During the period from April 1, 2025 to May 14, 2025, the Company sold 198,068shares of Common Stock of the Company pursuant to the New Keystone Purchase Agreement for net proceeds of $ 124,353. On April 9, 2025, the Company issued 211,000shares of its common stock in connection with the exercise of pre-funded warrants. Private Placement On April 21, 2025, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain investors. Pursuant to the Securities Purchase Agreement, up to 10,000shares of the Company’s Series D Preferred Stock, shall be purchased for an aggregate purchase price of up to $ 8million in one or more closings (each a “Closing”). On April 22, 2025, pursuant to the Securities Purchase Agreement, the Company issued and sold, and the investors named therein purchased, in a private placement (the “Private Placement”): 6,250shares of the Series D Preferred Stock for aggregate proceeds of approximately $ 5million, paid through the transfer of certain Transfer Shares (as defined in the Securities Purchase Agreement) in lieu of cash. The date of the first closing is referred to as the “First Closing Date.” Each additional closing of the Private Placement is at the option of the investors upon notice to the Company and subject to satisfaction of customary closing conditions. On April 22, 2025, the Company filed the Certificate of Designations of Rights and Preferences of the Series D Preferred Stock (the “Certificate of Designations”) for the purpose of designating and establishing the Company’s Series D Preferred Stock. With respect to dividend rights and rights on liquidation, winding-up and dissolution, the Company’s Series D Convertible Preferred Stock shall rank